Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for carisoprodol
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on carisoprodol or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on carisoprodol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose. Carisoprodol, a centrally acting muscle relaxant with a high abuse potential, has barbiturate-like properties at the GABA-A receptor, leading to central nervous system depression and desired effects. Its tolerance and dependence has been previously demonstrated in an animal model, and withdrawal has been described in several recent case reports. Many cases can be effectively managed with a short course (...) of benzodiazepines or antipsychotic agents. However, abrupt cessation in a patient with a history of long-term and high-dose carisoprodol abuse may result in symptoms that are more difficult for providers to treat.We present a case of a 34-year-old man with a long history of carisoprodol abuse who was found unresponsive after having ingested 7.5 grams of carisoprodol. He was intubated and admitted to the intensive care unit. He was given propofol, dexmedetomidine, fentanyl, ketamine, lorazepam, midazolam
Randomized, double-blind trial of carisoprodol 250 mg compared with placebo and carisoprodol 350 mg for the treatment of low back spasm. Carisoprodol, a centrally active skeletal muscle relaxant, is widely used for the treatment of acute, painful musculoskeletal disorders. When administered at a dose of 350 mg four times daily, carisoprodol demonstrated significant clinical benefit in its early clinical development trials; however, some unfavorable side effects, such as drowsiness and dizziness (...) , were reported. Recently, research was conducted to determine if a lower dose of carisoprodol would retain efficacy but improve tolerability compared to the higher 350-mg dose.The purpose of this multicenter study was to compare the efficacy and safety of carisoprodol 250-mg tablets four times daily to 350-mg tablets four times daily and to placebo in patients with acute, painful musculoskeletal spasm of the lower back.In this 1-week double-blind, placebo-controlled, parallel-group multicenter trial
Carisoprodol Top results for carisoprodol - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for carisoprodol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms
Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers. Some chronic pain patients on long-term opioid therapy also take centrally active skeletal muscle relaxants. One of those muscle relaxants is carisoprodol, a drug that is abused and capable of producing impairment. It would be of relevance to characterize the effects of an opioid and carisoprodol when taken together to determine if abuse liability-related measures and psychomotor impairment (...) are increased compared to when the drugs are taken alone.As part of a larger crossover, randomized, double-blind study, we examined the subjective and psychomotor responses of 15 healthy volunteers to four experimental conditions: placebo, 350 mg carisoprodol, 10mg oxycodone, and 350 mg carisoprodol followed 60 min later by 10mg oxycodone (intended to test the interaction of the two drugs when they were producing their maximal effects).Preliminary data analyses indicated that some of carisoprodol's effects
A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01421433 Recruitment Status : Unknown Verified
Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers. Carisoprodol is a centrally acting drug used to relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. There is evidence from different sources that this oral muscle relaxant is abused and that it is associated with impairment leading to arrests for "driving under the influence" as well as increased risk of automobile accidents. Its subjective and psychomotor effects (...) in healthy volunteers at therapeutic and supratherapeutic doses have not been well-characterized, and form the basis of this report. Fifteen healthy volunteers (8 males, 7 females) were administered 0, 350, and 700 mg of carisoprodol in separate sessions and for 6h afterwards they completed a battery of tests at fixed time intervals so as to assess the subjective and psychomotor effects of the drug. The supratherapeutic dose, 700 mg, increased visual analog scale ratings of terms that were more
Bioavailability of oral carisoprodol 250 and 350 mg and metabolism to meprobamate: A single-dose crossover study. Carisoprodol is a skeletal muscle relaxant indicated for use in the treatment of acute, painful musculoskeletal conditions. Two randomized, controlled clinical trials have reported that carisoprodol 250 mg QID was equally effective as and better tolerated than carisoprodol 350 mg QID.The primary objective of the current study was to determine the relative bioavailability (...) of carisoprodol and its metabolite, meprobamate, with singledose administration of 250- and 350-mg tablets. A secondary objective of the study was to determine whether lowering the carisoprodol dose would decrease plasma meprobamate concentrations.This single-dose, randomized, open-label, crossover study enrolled healthy volunteers. Each dose was administered with water in the morning; after a 7-day washout, subjects received the alternate dose. Blood samples were drawn at prespecified times over a 48-hour
A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00671502 Recruitment Status : Completed First Posted : May 5, 2008 Results First
Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. The effects of carisoprodol and a placebo were compared in a sample of 60 patients with the clinical diagnosis of myofascial pain-dysfunction syndrome using double-blind design. Carisoprodol failed to show a significantly greater effect than the placebo. The side effects were about the same with both agents.
Security and Efficacy of DorilaxÂ® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study (...) record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. (Delfos
Carisoprodol abuse in Texas, 1998â€“2003 Texas poison centers identified carisoprodol as a skeletal muscle relaxant that is subject to abuse, and this investigation explores the abuse reported by Texas poison centers.This study used data from six Texas poison centers to describe the epidemiology of carisoprodol abuse and drug identification (ID) calls from 1998 to 2003.Drug ID and abuse calls were 217% higher in 2003 than in 1998. Although eastern and central Texas contains 43% of the state's (...) population, this region reported 77% of all drug ID calls and 64% of abuse calls. For male patients, 51% of the calls were abuse calls and 37% were other human carisoprodol exposure calls. Patients from 13 to 19 years of age accounted for 17% of abuse calls and 9% of other human exposure calls. Among those human exposure calls with a known medical outcome, a higher percentage of abuse calls involved minor effects while a greater proportion of other human exposure calls involved outcomes that ranged from
Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. A double-blind study was carried out to determine the effectiveness of a muscle relaxant, carisoprodol, in the treatment of the low back syndrome, and to test whether this drug would produce any greater effect than an active sedative control. Forty-eight Mexican migrant farm laborers with acute lumbar strain and spasm were given either carisoprodol 350 mg, butabarbital 15 mg, or placebo, four times (...) daily for four days, and then were rated on pertinent symptoms, the degree of limitation of motion (by an objective finger-to-floor test), and overall improvement. In the 43 patients who could be statistically analyzed, carisoprodol was shown to be significantly more effective than butabarbital or placebo in producing improvement of all factors rated. This result suggests that the effects of carisoprodol are not due solely to sedative action, but are also related to its muscle relaxant activity.
Mass spectrometric analysis of carisoprodol and meprobamate in rat brain microdialysates We report the evaluation of several mass spectrometry-based methods for the determination of carisoprodol and meprobamate in samples obtained from the rat brain by in vivo intracranial microdialyis. Among the techniques that aspire to perform analyses without chromatographic separation and thereby increase throughput, chip-based nanoelectrospray ionization and the use of an atmospheric pressure solids (...) analysis probe fell short of requirements because of insufficient detection sensitivity and hard ionization, respectively. Although direct analysis in real time provided the required soft ionization, shortcomings of a tandem mass spectrometry-based assay also included inadequate detection sensitivity and, in addition, poor quantitative reproducibility. Therefore, liquid chromatography coupled with atmospheric pressure chemical ionization tandem mass spectrometry was developed to determine carisoprodol
Comparison of changes in the pain threshold following oral administration of carisoprodol, acetylsalicylic acid, and placebo. A trial on volunteers. 7022732 1981 10 14 2013 11 21 0347-9994 5 2 1981 Swedish dental journal Swed Dent J Comparison of changes in the pain threshold following oral administration of carisoprodol, acetylsalicylic acid, and placebo. A trial on volunteers. 77-80 Dahl E E Grenthe B B Lindqvist B B eng Clinical Trial Comparative Study Journal Article Randomized Controlled (...) Trial Sweden Swed Dent J 7706129 0347-9994 0 Placebos 21925K482H Carisoprodol R16CO5Y76E Aspirin D IM Administration, Oral Adult Aspirin administration & dosage pharmacology Carisoprodol administration & dosage pharmacology Clinical Trials as Topic Double-Blind Method Female Humans Male Middle Aged Pain physiopathology Placebos Sensory Thresholds drug effects 1981 1 1 1981 1 1 0 1 1981 1 1 0 0 ppublish 7022732
An experimental investigation of the change effected by the ingestion of carisoprodol, aspirin, codeine, and a placebo upon the threshold for deep pain induced by ultrasonic stimulation. 14402682 1998 11 01 2018 12 01 0077-8923 86 1960 Mar 30 Annals of the New York Academy of Sciences Ann. N. Y. Acad. Sci. An experimental investigation of the change effected by the ingestion of carisoprodol, aspirin, codeine, and a placebo upon the threshold for deep pain induced by ultrasonic stimulation. 147 (...) -61 HOLLIDAY A R AR DILLE J M JM eng Journal Article United States Ann N Y Acad Sci 7506858 0077-8923 0 Muscle Relaxants, Central 21925K482H Carisoprodol Q830PW7520 Codeine R16CO5Y76E Aspirin OM Analgesia Anesthesia Anesthesia and Analgesia Aspirin pharmacology Carisoprodol Codeine Humans Muscle Relaxants, Central pharmacology Pain Pain Management Ultrasonic Therapy ACETYLSALICYLIC ACID/pharmacology CODEINE/anesthesia and analgesia MUSCLE RELAXANTS/pharmacology 1960 3 30 1960 3 30 0 1 1960 3 30 0
CARISOPRODOL IN CEREBRAL PALSY: A CONTROLLED TRIAL. 14090619 1996 12 01 2018 12 01 0012-1622 5 1963 Dec Developmental medicine and child neurology Dev Med Child Neurol CARISOPRODOL IN CEREBRAL PALSY: A CONTROLLED TRIAL. 603-8 GOOCH J M JM eng Journal Article England Dev Med Child Neurol 0006761 0012-1622 0 Placebos 21925K482H Carisoprodol GWH6IJ239E Amobarbital OM Amobarbital Carisoprodol Cerebral Palsy Child Humans Infant, Newborn Placebos AMOBARBITAL CARISOPRODOL CEREBRAL PALSY CHILD INFANT
Double-blind trial of carisoprodol. 14001807 1998 11 01 2018 12 01 0012-1622 4 1962 Oct Developmental medicine and child neurology Dev Med Child Neurol Double-blind trial of carisoprodol. 499-506 WOODS G E GE eng Journal Article England Dev Med Child Neurol 0006761 0012-1622 21925K482H Carisoprodol OM Athetosis Carisoprodol Cerebral Palsy Double-Blind Method Humans ATHETOSIS CARISOPRODOL CEREBRAL PALSY 1962 10 1 1962 10 1 0 1 1962 10 1 0 0 ppublish 14001807
A Single Amino Acid Residue at Transmembrane Domain 4 of the Î± Subunit Influences Carisoprodol Direct Gating Efficacy at GABAA Receptors The muscle relaxant carisoprodol has recently been controlled at the federal level as a Schedule IV drug due to its high abuse potential and consequences of misuse, such as withdrawal syndrome, delusions, seizures, and even death. Recent work has shown that carisoprodol can directly gate and allosterically modulate the type A GABA (GABAA) receptor (...) . These actions are subunit-dependent; compared with other GABAA receptors, carisoprodol has nominal direct gating effects in α3β2γ2 receptors. Here, using site-directed mutagenesis and whole-cell patch-clamp electrophysiology in transiently transfected human embryonic kidney 293 cells, we examined the role of GABAA receptor α subunit transmembrane domain 4 (TM4) amino acids in direct gating and allosteric modulatory actions of carisoprodol. Mutation of α3 valine at position 440 to leucine (present
Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Forty-three of fifty-eight (74.1%) female patients with fibromyalgia completed an eight-week treatment period testing the combination of carisoprodol, paracetamol (acetaminophen) and caffeine versus placebo. Twenty-three patients received placebo and twenty active medication. In the placebo group 56.5% of the patients used additional (...) ). In the active treatment group increased pressure pain threshold after eight weeks was found at 70% of the sites measured, while the pressure pain threshold was increased at only 30% of the sites in the placebo group. In the placebo group improvement was found for the pain and sleep quality (p less than 0.05). This improvement may in part be due to the large amounts of extra medication in this group. Thus, the combination of carisoprodol and paracetamol (acetaminophen) and caffeine are effective
Double-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm. The objective of this placebo-controlled trial was to determine the efficacy and safety of carisoprodol (Soma, MedPointe Pharmaceuticals, Somerset, NJ, USA), a centrally acting skeletal muscle relaxant used to treat acute, painful musculoskeletal conditions, at a dosage of 250 mg three times daily and at bedtime in patients with acute, painful muscle spasm of the lower back.This (...) was a 7-day, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Qualified patients were randomly assigned to treatment with carisoprodol 250-mg tablets (n = 277) or matching placebo tablets (n = 285). The coprimary efficacy endpoints were patient-rated global impression of change and patient-rated relief from starting backache scored on a 5-point rating scale. The primary analysis was on study Day 3. Four secondary endpoints were also assessed: (1) the Roland-Morris